HOME >> BIOLOGY >> NEWS
Universal flu vaccine being tested on humans

Ghent, Belgium -- A universal influenza vaccine that has been pioneered by researchers from VIB and Ghent University is being tested for the first time on humans by the British-American biotech company Acambis. This vaccine is intended to provide protection against all A strains of the virus that causes human influenza, including pandemic strains.

Flu

Influenza is an acute infection of the bronchial tubes and is caused by the influenza virus. Flu is probably one of the most underestimated diseases: it is highly contagious and causes people to feel deathly ill. An average of 5% of the worlds population is annually infected with this virus. This leads to 3 to 5 million hospitalizations and 250,000 to 500,000 deaths per year. In Belgium, an average of 1500 people die of flu each year. A more severe flu year - such as the winter of 1989-1990 - claimed in our country 4500 victims. Besides the annual flu epidemics, there is the possibility of a pandemic, which occurs every 10 to 30 years and causes more severe disease symptoms and a higher mortality rate. During the pandemic caused by the Spanish flu in 1918-1919, the number of deaths worldwide even rose to over 50 million.

Why an annual vaccine?

Todays flu vaccines need to be adapted every year and, consequently, they must also be administered again every year. The external structure of the flu virus mutates regularly, giving rise to new strains of flu. Due to these frequent mutations, the virus is able to elude the antibodies that have been built up during a previous infection or vaccination. This is why we run the risk of catching the flu each year and also why a new flu vaccine must be developed each year. A universal flu vaccine that provides broad and lifelong protection - like the vaccines we have for polio, hepatitis B or measles - is not yet available.

Universal flu vaccine

In the 1990s, VIB researchers connected to Ghent University, under
'"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
17-Jul-2007


Page: 1 2

Related biology news :

1. Universal design tackles little things with big impact
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
4. Handicapping tuberculosis may be the way to a better vaccine
5. Developing a more effective vaccine for tuberculosis
6. New target for HIV/AIDS drugs and vaccine discovered
7. Genomic analysis uncovers new targets for HIV vaccine
8. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
9. From clinical cancer research: rethinking therapeutic cancer vaccine trials
10. Paving the way toward a vaccine against Alzheimers disease
11. Mucosal-surface immune function discoveries could boost vaccine research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2020)... ... June 23, 2020 , ... In its June 22 online post, business and ... L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex ... 16 that starting July 5 it would begin offering free tissue stem ...
(Date:6/11/2020)... Fla. (PRWEB) , ... June 08, 2020 , ... ... demand for masks and other protective measures to protect workers in the medical ... and their dedicated staffs who valiantly risk their lives every day to provide ...
(Date:6/2/2020)... ... June 02, 2020 , ... ... and RFID labeling software developer and solutions provider, today reported that the ... labeling accuracy and compliance by 100%, resulting in greater efficiency for global ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... life sciences industry, today announced the release of its signature product called ... Science Liaisons (MSLs) and other field medical professionals. , Beacon helps ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
(Date:7/10/2020)... ... July 09, 2020 , ... In most ... used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate ... Dr MA has been using the zebrafish model to investigate the causes of ...
Breaking Biology Technology:
Cached News: